Remix Therapeutics
Latest round
- Series B
Last raised
- Jan 2024
Total raised
- $177M
Investors
- 9
About Remix Therapeutics
Founded in 2018 and headquartered in Watertown, US, Remix Therapeutics specializes in RNA-targeted therapy development.Remix Therapeutics specializes in innovative RNA-targeted therapies through its proprietary drug discovery platform, focusing on modulating RNA processing with small molecules. Its lead product, REM-422, is a first-in-class small molecule mRNA degrader targeting MYB pre-mRNA, which is linked to several diseases, including adenoid cystic carcinoma.Remix Therapeutics generates revenue through strategic collaborations, licensing agreements, and clinical trial partnerships, with potential future income from product sales, particularly from REM-422. Revenue streams include upfront payments, milestone payments tied to clinical trial advancement, and royalties on future sales of marketed products. The timeline for these initiatives is currently aligned with the clinical advancement of their therapies.
Who invested in Remix Therapeutics
9 investors across 3 rounds
See all investors in Remix Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Remix Therapeutics
Who invested in Remix Therapeutics?
Remix Therapeutics has 9 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Remix Therapeutics raised?
Remix Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Remix Therapeutics last raise money?
Remix Therapeutics's most recent round on record is a Series B, in Jan 2024.
What does Remix Therapeutics do?
Founded in 2018 and headquartered in Watertown, US, Remix Therapeutics specializes in RNA-targeted therapy development.
Where is Remix Therapeutics headquartered?
Remix Therapeutics is headquartered in Watertown, US.
Which VCs invest in companies like Remix Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Remix Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Remix Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.